The Italian Multiple Sclerosis Database Network (MSDN): The risk of worsening according to IFNβ exposure in multiple sclerosis

Multiple Sclerosis

Volumn 12, Issue 5, 2006, Pages 578-585

  Trojano, Maria ^a   Russo, Pierluigi ^b   Fuiani, Aurora ^a   Paolicelli, Damiano ^a   Di Monte, Elisabetta ^a   Granieri, Enrico ^c   Rosati, Giulio ^d   Savettieri, Giovanni ^e   Comi, Giancarlo ^f   Livrea, Paolo ^a   Comi, G ^g   Bertolotto, A ^g   Durelli, L ^g   Mancardi, G L ^g   Montanari, E ^g   Stecchi, S ^g   Gallo, P ^g   Capra, R ^g   Zorzon, M ^g   Ghezzi, A ^g   Granieri, E ^g   Meucci, G ^g   Cosi, V ^g   Pozzilli, C ^g   Piazza, G ^g   Amato, M P ^g   Gambi, D ^g   Livrea, P ^g   Bonavita, V ^g   Quattrone, A ^g   Savettieri, G ^g   Reggio, A ^g   Marrosu, M G ^g   Rosati, G ^g   Messina, C ^g   more..

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF SASSARI   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g NONE

Author keywords

IFNP; Long term effectiveness; Multiple sclerosis; Observational studies

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; BETA INTERFERON; BIOLOGICAL RESPONSE MODIFIER; IMMUNOLOGICAL ADJUVANT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HUMAN; INFORMATION PROCESSING; ITALY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK FACTOR; SCORING SYSTEM; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME; ANALYSIS OF VARIANCE; CLINICAL TRIAL; COMPARATIVE STUDY; DEMOGRAPHY; DISABILITY; EVALUATION; MIDDLE AGED; MULTICENTER STUDY; REGRESSION ANALYSIS; RISK; STATISTICS; TIME;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL RESPONSE MODIFIERS; COHORT STUDIES; DATABASES; DEMOGRAPHY; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON-BETA; ITALY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RISK; TIME FACTORS; TREATMENT OUTCOME;

EID: 33749118113     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506070620     Document Type: Article

References (39)

1. Devonshire V. Clinical databases in multiple sclerosis: patient management and research. Int Mult Scler J 2001; 8: 56-66.
2. Pincus T, Stein CM. What is the best source of useful data on the treatment of rheumatoid arthritis: clinical trials, clinical observations, or clinical protocols? J Rheumatol 1995; 22: 1611-17.
3. Weinshenker BG. Databases in MS research: pitfalls and promises. Mult Scler 1999; 5: 206-11.
4. Wolfe F, Pincus T. Data collection in the clinic. Rheum Dis Clin North Am 1995; 21: 321-58.
5. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-92.
6. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
7. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Ritcher JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
8. Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, Richert JR et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1997; 49: 358-63.
9. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
10. Jonnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of the phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-76.
11. Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-19.
12. Detre KM, Guo P, Holubkov R, Califf RM, Sopko G, Bach R et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the by-pass Angioplasty Revascularization Investigation (BARI). Circulation 1999; 99: 633-40.
13. Vollmer TL, Ni W, Stanton S, Hadjimichael O. The NARCOMS patient registry: a resource for investigators. Int J MS Care 1999; 1: 12-15.
14. Weinstock-Guttmar B, Jacobs LD, Brownscheidle CM, Baier M, Rea DF, Apatoff BR et al. Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium. Mult Scler 2003; 9: 293-98.
15. Paty D, Studney D, Redekop K, Lublin F. MS COSTAR: a computerized patient record adapted for clinical research purposes. Ann Neurol 1994; 36: S134-35.
16. Koch-Henriksen N, Rasmussen S, Stenager E, Madsen M. The Danish Multiple Sclerosis Registry. History, data collection and validity. Dan Med Bull 2001; 48: 91-94.
17. Celius EG, Vandvik B. Multiple sclerosis in Oslo, Norway: prevalence on 1 January 1995 and incidence over a 25-year period. Eur J Neurol 2001; 8: 463-69.
18. Confavreux C, Compston DAS, Hommes OR, McDonald WI, Thompson AJ. EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 1992; 55: 671-76.
19. Butzkueven H, Chapman J, Cristiano E, Grand'-Maison F, Izquierdo G, Kappos L et al. MSBase: an international, online registry dedicated to evaluating outcomes data in multiple sclerosis. In: Abstracts from the 19th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. 17-20 September 2003, Milan, Italy.
20. Trojano M, Granieri E, Rosati G, Savettieri G, Livrea P, Comi G. The multiple sclerosis database network: an Italian source of valuable data for clinical and research studies. In: Abstracts from the 19th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. 17-20 September 2003, Milan, Italy.
21. Trojano M, Liguori M, Paolicelli D, Zimatore GB, De Robertis F, Avolio C et al. An independent post-marketing study in southern Italy. Mult Scler 2003; 9: 451-57.
22. Milanese C, La Mantia L, Palumbo R, Martinelli V, Murialdo A, Zaffaroni M et al. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 2003; 74: 1689-92.
23. Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, D'Amico R et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003; 361: 545-52.
24. Mechati S, Peyro-St-Paul H. iMed: a new electronic database for monitoring patients with multiple sclerosis. Mult Scler 2001; 7: S31.
25. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
26. Rosenbaum PR, Rubin DB. The central role of propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
27. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-63.
28. D'Agostino Jr RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-81.
29. Stenestrand U, Wallentin L for the Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-36.
30. Gum PA, Thamilarasan M, Watanabe J, Blackstone EH, Lauer MS. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis. JAMA 2001; 286: 1187-94.
31. Russo P, Paolillo A, Caprino L, Bastianello S, Bramanti P. Effectiveness of interferon beta treatment in relapsing-remitting multiple sclerosis: an Italian cohort study. J Eval Clin Pract 2004, 10: 511-18.
32. Mumford CJ, Fraser MB, Wood NW, Compston DA. Multiple sclerosis in the Cambridge Health Authority. J Neurol Neurosurg Psychiatry 1992; 55: 877-82.
33. Rice-Oxley M, Williams ES, Rees JE. A prevalent survey of multiple sclerosis in Sussex. J Neurol Neurosurg Psychiatry 1995; 58: 27-30.
34. Trojano M, Avolio C, Manzari C, Calò A, De Robertis F, Serio G et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 1995; 58: 300-306.
35. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112: 133-46.
36. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 4. Application to planning and interpretation of clinical therapeutic trials. Brain 1991; 114: 1057-67.
37. Trojano M, Liguori M, Zimatore GB, Bugarini R, Avolio C, Paolicelli D et al. Age-related disability in multiple sclerosis. Ann Neurol 2002; 51: 475-80.
38. Waubant E, Vukusic S, Gignoux L, Dubief FD, Achiti I, Blanc S et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003; 61: 184-89.
39. Benson K, Hartz A. Comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342: 1878-86.